Xeljanz — Competitive Intelligence Brief

Xeljanz (Tofacitinib Citrate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor.

marketed JAK inhibitor Janus kinase (JAK) enzymes Small molecule

Target snapshot

Xeljanz (Tofacitinib Citrate) — Pfizer. Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xeljanz TARGET	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Pf-07293893	pf-07293893	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) pathway	Not available
Xeljanz	tofacitinib	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Tofacitinib with methotrexate	Tofacitinib with methotrexate	Pfizer	marketed	JAK inhibitor + DMARD	JAK1, JAK3 (tofacitinib); dihydrofolate reductase (methotrexate)
Chronic- PF-06480605 50 mg SC Q4W	chronic-pf-06480605-50-mg-sc-q4w	Pfizer	marketed	JAK inhibitor	JAK pathway
Rinvoq	upadacitinib	AbbVie Inc.	marketed	JAK inhibitor	Janus kinase (JAK) enzymes, particularly JAK1 and JAK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

1. Pfizer · 19 drugs in this class
2. Aclaris Therapeutics, Inc. · 2 drugs in this class
3. Beijing Friendship Hospital · 2 drugs in this class
4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
5. CAGE Bio Inc. · 1 drug in this class
6. CTI BioPharma · 1 drug in this class
7. Celgene · 1 drug in this class
8. Fred Hutchinson Cancer Center · 1 drug in this class
9. LEO Pharma · 1 drug in this class
10. McMaster University · 1 drug in this class